山河药辅(300452) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 reached ¥165,215,292.43, representing a year-on-year increase of 17.41%[4] - Net profit attributable to shareholders for Q3 2022 was ¥28,468,579.65, up 47.69% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥25,347,762.22, reflecting a 60.89% increase year-on-year[4] - The company reported a significant improvement in profitability, with a net profit growth of 47.69% in Q3 2022 compared to the same quarter last year[7] - The net profit for the third quarter of 2022 was CNY 93,461,300.05, an increase of 31.9% compared to CNY 70,859,435.00 in the same period last year[24] - The operating profit for the quarter was CNY 105,348,970.98, up from CNY 81,980,101.56, reflecting a growth of 28.5% year-over-year[24] - The total revenue from operating activities was CNY 440,694,713.22, compared to CNY 369,585,368.55 in the previous year, indicating an increase of 19.2%[26] - The company reported a total comprehensive income of CNY 93,461,300.05, compared to CNY 70,859,435.00 in the previous year, marking a growth of 31.9%[25] - Basic and diluted earnings per share for the quarter were both CNY 0.40, up from CNY 0.31 in the same period last year, representing a growth of 29.0%[25] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥1,037,580,019.65, an increase of 7.79% from the end of the previous year[4] - Current assets totaled ¥571,326,276.68, a rise of 3.9% from ¥552,823,876.60 at the start of the year[20] - The total liabilities increased to ¥292,120,152.63, compared to ¥256,665,812.73 at the beginning of the year, marking a rise of 13.7%[21] - The equity attributable to the parent company reached ¥680,767,283.21, an increase from ¥640,000,201.75, reflecting a growth of 6.4%[21] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥57,097,827.18, up 52.67% year-on-year, primarily due to increased cash receipts from sales[11] - The cash flow from operating activities generated a net amount of CNY 57,097,827.18, which is a 52.7% increase from CNY 37,398,682.03 in the same quarter last year[26] - The company's cash and cash equivalents at the end of the reporting period were ¥83,437,400, reflecting a 30.97% increase year-on-year[11] - The cash and cash equivalents at the end of the period were CNY 83,437,409.98, an increase from CNY 63,709,279.69 at the end of the previous year[27] - The net cash flow from investing activities was negative at CNY -42,031,724.76, worsening from CNY -13,309,878.48 in the same quarter last year[27] - The total cash outflow from financing activities was CNY 92,676,991.49, slightly higher than CNY 91,783,425.39 in the same period last year[27] Research and Development - Research and development expenses for the year-to-date period amounted to ¥24,076,800, representing a 46.98% increase year-on-year due to increased R&D investment[10] - Research and development expenses increased significantly to ¥24,076,821.87, compared to ¥16,381,375.50 in the previous period, reflecting a growth of 47.0%[22] - The company has continued to focus on R&D innovation and customer import substitution to achieve steady performance growth despite external challenges[7] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 19,281[13] - The largest shareholder, Yin Zhenglong, holds 26.89% of shares, totaling 63,057,454 shares[13] - Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. holds 11.19% of shares, totaling 26,254,059 shares[13] - Liu Tao, a natural person, holds 3.13% of shares, totaling 7,329,343 shares[14] - The total number of restricted shares held by Yin Zhenglong is 47,293,089, with no shares released during the period[16] - The total number of restricted shares at the end of the period is 48,490,334[17] - The company has a total of 90 natural person shareholders with restricted shares totaling 852,540[17] - The company has not reported any changes in the number of preferred shareholders[15] Other Information - The company has not disclosed any new product or technology developments in this report[18] - There are no significant mergers or acquisitions reported in this quarter[18]